Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB

Oncotarget. 2018 Jul 31;9(59):31559. doi: 10.18632/oncotarget.25943.

¹ Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
² Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
³ Division of Pulmonary Medicine, Department of Internal Medicine, Chang Gung Medical Foundation Linko Branch, Taoyuan, Taiwan.
⁴ Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁵ School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁶ Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁷ Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
⁸ Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.24146.].